In my experience the borrow rate of $Gamida Cell Ltd.(GMDA)$ soars after an unusually high volume day. What I think happens is brokers allow more shares to be sold short than they can find, A supply vs. demand problem. they have to raise the borrow rate to try and increase supply and also reduce demand. This sorts itself out in a pump and dump rather quickly. But every now and then the news attracts investors and traders. Traders sell and take profits. Investors buy and hold. I am currently playing 2 of these types of stock plays. LUCY and SATX. I am a lousy trader but that portfolio is up 90% YTD. This appears to be a similar play. So my plan is take a very small position and then wait out the shorts. Sooner or later they cave if its a legitimate
$Gamida Cell Ltd.(GMDA)$ What am I missing here? The rate to borrow for shorts is 156% which would indicate a significant amount of pessimism around this stock. Yet we're in a boiler room? Both can't be correct so why would professional traders keep attacking the share price at a greater expense with all that's been made public? Apologies if this is mundane, I don't play options.
Option Movers | Investors Bet NVIDIA Will Continue to Soar; Tesla in Focus After Price Cuts
Market OverviewThe S&P 500 eked out a slim gain on Tuesday (Apr. 18th) after strength in some big technology stocks countered disappointing quarterly reports from $Johnson & Johnson(JNJ)$ and $Goldman Sachs(GS)$ as first-quarter earnings season kicked into gear.Regarding the options market, a total volume of 31,074,588 contracts was traded, up 2% from the previous trading day.Top 10 Option VolumesTop 10: $SPY(SPY)$; $QQQ(QQQ)$; $VIX(VIX)$; $NVDA(NVDA)$; $IWM(IWM)$;
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.
04-25
Delisting
Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities